RESOURCES

/

FIND A SPECIALIST

/

CONTACT

Daniel C. Cattran, M.D.

University of Toronto

Dr. Cattran is a graduate of the University of Toronto Medical School. He did his postgraduate training in both Toronto, Canada and Sydney, Australia. He is currently a Professor of Medicine at the University of Toronto and a senior scientist at the Toronto General Research Institute.

Grant support for his work has come from the Kidney Foundation of Canada, PSI, the National Institutes of Health, and the Canadian Institutes for Health Research. Dr. Cattran’s major research work has been in the field of glomerular diseases. He was the principal organizer and remains the Chair of the Toronto Glomerulonephritis Registry, which currently includes over 10,000 cases of biopsy-proven glomerulonephritis. He has published over 200 articles in peer-reviewed journals and more than 30 book chapters related to the natural history, outcome and treatment studies of glomerulonephritis.

In recognition of his career in clinical investigation, the Kidney Foundation of Canada awarded him the Medal for Research Excellence in 2005. He was also the recipient of the Conrad Pirani Award from Columbia University in 2008.

He has served on the editorial board of both the American Journal of Kidney Disease and the Journal of the American Society of Nephrology, and is currently an associate editor for Kidney International. He is on the editorial board of Up-to-Date and is currently the author/co-author of several of their cards in glomerular disease.

He has held a number of positions in the Canadian Society of Nephrology, including a term as president. He’s also served in various positions within the American Society of Nephrology, including two terms on the Post Graduate Education Committee, and, currently, as a member of the Glomerular Disease Advisory Group.

Selected Publications
Hodgin JB, Berthier CC, John R, Grone E, Porubsky S, Gröne HJ, Herzenberg AM, Scholey JW, Hladunewich M, Cattran DC, Kretzler M, Reich HN. The molecular phenotype of endocapillary proliferation: novel therapeutic targets for IgA nephropathy. PLoS One. 2014; 9(8), e103413.

Dhaun N, Bellamy CO, Cattran DC, Kluth DC. Utility of renal biopsy in the clinical management of renal disease. Kidney Int. 2014; 85(5), 1039-1048.

Lee T, Biddle AK, Lionaki S, Derebail VK, Barbour SJ, Tannous S, Hladunewich MA, Hu Y, Poulton CJ, Mahoney SL, Charles Jennette J, Hogan SL, Falk RJ, Cattran DC, Reich HN, Nachman PH. Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. Kidney Int. 2014; 85(6), 1412-1420.

Ashraf S, Gee HY, Woerner S, Xie LX, Vega-Warner V, Lovric S, Fang H, Song X, Cattran DC, Avila-Casado C, Paterson AD, Nitschké P, Bole-Feysot C, Cochat P, Esteve-Rudd J, Haberberger B, Allen SJ, Zhou W, Airik R, Otto EA, Barua M, Al-Hamed MH, Kari JA, Evans J, Bierzynska A, Saleem MA, Böckenhauer D, Kleta R, El Desoky S, Hacihamdioglu DO, Gok F, Washburn J, Wiggins RC, Choi M, Lifton RP, Levy S, Han Z, Salviati L, Prokisch H, Williams DS, Pollak M, Clarke CF, Pei Y, Antignac C, Hildebrandt F. ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. J Clin Invest. 2013; 123(12), 5179-5189.

Gadegbeku CA, Gipson DS, Holzman LB, Ojo AO, Song PX, Barisoni L, Sampson MG, Kopp JB, Lemley KV, Nelson PJ, Lienczewski CC, Adler SG, Appel GB, Cattran DC, Choi MJ, Contreras G, Dell KM, Fervenza FC, Gibson KL, Greenbaum LA, Hernandez JD, Hewitt SM, Hingorani SR, Hladunewich M, Hogan MC, Hogan SL, Kaskel FJ, Lieske JC, Meyers KE, Nachman PH, Nast CC, Neu AM, Reich HN, Sedor JR, Sethna CB, Trachtman H, Tuttle KR, Zhdanova O, Zilleruelo GE, Kretzler M. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int. 2013; 83(4), 749-756.

Irazabal MV, Eirin A, Lieske J, Beck LH, Sethi S, Borland TM, Dillon JJ, Nachman PH, Nasr SH, Cornell LD, Leung N, Cattran DC, Fervenza FC. Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study. Nephrol Dial Transplant. 2013; 28(1), 137-146.

University of Toronto | Toronto General Research Institute

Related News

NEWS

NephCure Launches National Coalition to Advocate f...

JULY 27, 2023

NEWS

NephCure Patient & Youth Summit 2024 Unites Rare K...

JULY 27, 2023

NEWS

A Breakthrough in Understanding of the Cause of So...

JULY 27, 2023

NEWS

Introducing a New Destination for the Rare Kidney ...

JULY 27, 2023

Sign up to get NephCure’s latest updates.

SIGN UP
This field is for validation purposes and should be left unchanged.